» Articles » PMID: 12213076

Do Structurally Similar Molecules Have Similar Biological Activity?

Overview
Journal J Med Chem
Specialty Chemistry
Date 2002 Sep 6
PMID 12213076
Citations 202
Authors
Affiliations
Soon will be listed here.
Abstract

To design diverse combinatorial libraries or to select diverse compounds to augment a screening collection, computational chemists frequently reject compounds that are > or =0.85 similar to one already chosen for the combinatorial library or in the screening set. Using Daylight fingerprints, this report shows that for IC(50) values determined as a follow-up to 115 high-throughput screening assays, there is only a 30% chance that a compound that is > or = 0.85 (Tanimoto) similar to an active is itself active. Although this enrichment is greater than that found with random screening and docking to three-dimensional structures, this low fraction of actives within similar compounds occurs not only because of deficiencies in the Daylight fingerprints and Tanimoto similarity calculations but also because similar compounds do not necessarily interact with the target macromolecule in similar ways. The current study emphasizes the statistical or probabilistic nature of library design and that perfect results cannot be expected.

Citing Articles

Virtual screening: hope, hype, and the fine line in between.

Nada H, Meanwell N, Gabr M Expert Opin Drug Discov. 2025; 20(2):145-162.

PMID: 39862145 PMC: 11844436. DOI: 10.1080/17460441.2025.2458666.


Coverage bias in small molecule machine learning.

Kretschmer F, Seipp J, Ludwig M, Klau G, Bocker S Nat Commun. 2025; 16(1):554.

PMID: 39788952 PMC: 11718084. DOI: 10.1038/s41467-024-55462-w.


In Silico Study of the Potential Inhibitory Effects on DNA Gyrase of Some Hypothetical Fluoroquinolone-Tetracycline Hybrids.

Lungu I, Oancea O, Rusu A Pharmaceuticals (Basel). 2024; 17(11).

PMID: 39598450 PMC: 11597511. DOI: 10.3390/ph17111540.


A computational and machine learning approach to identify GPR40-targeting agonists for neurodegenerative disease treatment.

Siddiqui A, Badraoui R, Alshahrani M, Snoussi M, Jahan S, Siddiqui M PLoS One. 2024; 19(10):e0306579.

PMID: 39378198 PMC: 11481007. DOI: 10.1371/journal.pone.0306579.


Merging multi-omics with proteome integral solubility alteration unveils antibiotic mode of action.

Maity R, Zhang X, Liberati F, Scribani Rossi C, Cutruzzola F, Rinaldo S Elife. 2024; 13.

PMID: 39329363 PMC: 11434622. DOI: 10.7554/eLife.96343.